CELLEBRITE DI LTD Logo
IL0011794802
A3D00S
CLBT

CELLEBRITE DI LTD

Loading quotes...

Forecast

The analysts' average price target is €12.82 (+22.56%). The median is €13.15 (+25.72%).

Buy
  9
Hold
  0
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Cellebrite plans to relocate corporate headquarters from Israel to the US

    Cellebrite’s board has approved a restructuring that would place a new US parent company at the top of the group’s corporate structure. The move is subject to shareholder and regulatory approval and is expected to be completed by H1 2027. CEO Shiv Ramji cites growth in key markets, greater attractiveness to investors and possible index inclusion as reasons; further details will be disclosed via SEC filings. » More on de.investing.com


  • Cellebrite brings AI tool Genesis to enterprises and expands international availability

    Cellebrite is making its AI-powered investigation tool Genesis generally available to enterprises and is expanding the market to countries such as Australia, the United Kingdom and soon the EU. Genesis, which has already been used by law enforcement since June 2026, is now intended for internal investigations such as employee misconduct, financial fraud, M&A due diligence, insider threats and compliance. At the same time, the company is introducing the Deep Investigator feature to extract hard-to-access mobile data and plans to add additional features and data sources in the coming months. » More on de.investing.com


  • Cellebrite DI: 30% sell-off as entry opportunity, JPMorgan sees over 40% potential

    Cellebrite DI was punished by more than 30% at times after the Q2 results and the surprise CEO change, but is being viewed as a buying opportunity. Criticisms include longer sales cycles and slower monetization progress on product updates, while the core story remains intact according to the report. JPMorgan sees more than 40% upside; the price-to-sales (P/S) ratio is below 5 after the pullback and Shiven Ramji takes over the CEO role immediately. » More on finanzen.net


  • Cellebrite DI falls to 52-week low despite strong metrics

    Cellebrite DI shares fell to 10.01 USD, reaching a new 52-week low, despite a roughly 9% gain over the past 12 months. Analysts at InvestingPro currently view the stock as undervalued with significant upside potential. The company reports high gross profit margins of 83.9% and more cash than debt, and beat expectations in Q1 2026 with EPS of 0.12 USD; revenue was 128.3 million USD. TD Cowen reaffirmed its buy rating and set a price target of 23 USD. » More on de.investing.com


  • Cellebrite technology used by Russia to extract data from opposition iPhone after sales ban

    University of Toronto’s Citizen Lab and legal records show Russian investigators used Cellebrite’s UFED to access opposition politician Andrey Pivovarov’s iPhone in June 2021, months after Cellebrite said it stopped sales to Russia. Evidence suggests the device extracted contacts and messages tied to Open Russia and contributed to subsequent surveillance and phishing operations against dissidents. Cellebrite says post‑March 2021 use is unauthorized and legacy hardware would lack support, while critics call for stronger legal and technical controls including a killswitch. » More on forbes.com

Financials

In the last quarter, CELLEBRITE DI LTD had revenue of €114.9m and net profit of €5.58m
(EUR) June 2026
YoY
Revenue 114.9m 19.56%
Gross profit 92.82m 14.44%
Net profit 5.58m 66.22%
EBITDA 14.49m 44.03%

Fundamentals

Metric Value
Market capitalization
€2.9bn
Number of shares
251.34m
52-week high/low
€18.12 - €8.69
Dividends No
Beta
1.05
P/E ratio
53.95
PEG ratio
0.62
P/B ratio
5.84
P/S ratio
6.21

Company profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations. Its DI platform allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations and solutions are used in a various case, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, intellectual property theft, and civil litigation. The company's Universal Forensic Extraction Device solution addresses problems in accessing digital information, including complicated device locks, encryption barriers, deleted and unknown content, and other obstacles that can prevent critical evidence from coming to light. It also offers Seeker solution that provides the ability to analyze video footage; OSINT Analyze, a real-time deep dive solution used to analyze open-source information, such as the surface web, deep web, and the dark web; and Crypto Tracer, which analyzes blockchain transactions together with related data from an extensive list of sources to identify and categorize wallets, and transactions. The company serves federal and state and local agencies, as well as enterprise companies and service providers. It has operations in the United States, Germany, Singapore, Australia, Brazil, United Kingdom, France, Canada, Japan, and India. The company was incorporated in 1999 and is based in Petah Tikva, Israel. Cellebrite Mobile Synchronization Ltd. operates as a subsidiary of Sun Corporation.

Name
CELLEBRITE DI LTD
CEO
Shiv Ramji
Headquarters Petah Tikva, hm
Israel
Website
Industry
Health Care Technology
IPO
06/11/2020
Employees 1,285

Ticker symbols

Exchange Symbol
NASDAQ
CLBT
🍪

Parqet  uses cookies. Learn more